PHI with Chronic idiopathic thrombocytopenic purpura (ITP)
How does this condition affect your private health insurance?
Chronic Idiopathic Thrombocytopenia (ITP), now frequently termed Immune Thrombocytopenia, is an autoimmune disorder where the body's immune system mistakenly attacks and destroys its own platelets. This destruction leads to a low platelet count, impairing normal blood clotting and significantly increasing the risk of bleeding. Symptoms can range from mild bruising and petechiae to more severe internal hemorrhages. While often idiopathic (unknown cause), it can also be secondary to other conditions. Management aims to elevate platelet counts and prevent bleeding, commonly involving corticosteroids, intravenous immunoglobulins, or thrombopoietin receptor agonists.
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Weeks to several months for initial stabilization; often an acute phase.
Duration of Illness (Lifetime)
Often a chronic, lifelong condition requiring ongoing monitoring and management, though spontaneous remission can occur in some adults.
Cost of Treatment (Initial)
Moderately high (e.g., hundreds to several thousands of euros/dollars for initial diagnosis and first-line treatments like steroids or IVIg, potentially including hospital stays).
Cost of Treatment (Lifetime)
Very high (e.g., tens of thousands to hundreds of thousands of euros/dollars, especially with long-term medication, newer biologics, repeated treatments, or splenectomy).
Mortality Rate
Low (approximately 1-5%), primarily due to severe bleeding, particularly intracranial hemorrhage, if untreated or in severe refractory cases.
Risk of Secondary Damages
High (e.g., bleeding complications like bruising, petechiae, epistaxis, menorrhagia; fatigue; and side effects from treatments like corticosteroids or immunosuppressants).
Probability of Full Recovery
Variable; approximately 70-80% of children with acute ITP recover completely, but for adults with chronic ITP, spontaneous complete recovery is less common (around 10-20%), though sustained remission is possible with treatment.
Underlying Disease Risk
Moderate (e.g., ~10-20% of 'idiopathic' cases may later be found secondary to conditions like H. pylori infection, HIV, HCV, autoimmune diseases like lupus, or lymphoproliferative disorders).